Login to Your Account



Daiichi Sankyo reveals 4 patient deaths in halted nimotuzumab trial

By Dan Poppy
Contributing Writer

Wednesday, May 14, 2014

Tokyo-based Daiichi Sankyo Co. Ltd. discontinued a phase III trial for nimotuzumab on the recommendation of an independent data monitoring committee after four treatment-related deaths were observed, all in the nimotuzumab arm.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription